AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01522196 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Normal Saline)
Description: 48 hour continuous infusion delivered intravenously (IV)at a rate of 110µg/kg/hr.
Study NCT02415829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine plus oxaliplatin
Description: The neoadjuvant chemotherapy consisted of oxaliplatin, 130 mg/m² on day 1, with capecitabine, 1000 mg/m² twice daily for 14 days every 3 weeks (the XELOX regimen)
Study NCT02737371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318 Dose level A oral
Description: Adverse events days 1-10
Study NCT02737371 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo dose level A oral
Description: Placebo adverse events days 1-10
Study NCT00248911 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness based meditation program
Description: Subjects will participate in an intervention consisting of group and individual instruction in a meditation-based practice of stress-reduction and cognitive-affective-behavioral learning.
Study NCT01912443 — intervention group
Intervention type: DRUG
Intervention: bevacizumab
Description: 5 mg/Kg, IV (in the vein) on day 1 and day 14 of each 28 day cycle. Number of Cycles: until progression.
Study NCT02264379 — intervention group
Intervention type: RADIATION
Intervention: normal fractionated irradiation
Description: 25\*2 Gy (once a day, 5 days a week)
Study NCT02264379 — intervention group
Intervention type: RADIATION
Intervention: hypo fractionated irradiation
Description: 3\*10 Gy (once a day, 2-3 days a week)
Study NCT01010490 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Longitudinal U/S (Infiniti system, Alcon, USA)
Description: comparison of efficacy and safety
Study NCT01010490 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Longitudinal U/S (LEGACY 20000, Alcon, USA)
Description: Interrupted energy modality
Study NCT02221635 — intervention group
Intervention type: PROCEDURE
Intervention: rTMS + risperidone
Description: Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks,than 2 sessions per week for 2 months, repeat that for 12 months. Meanwhile,risperidone (2-4 mg) was took orally.
Study NCT02221635 — intervention group
Intervention type: DRUG
Intervention: Risperidone
Description: Risperidone (2-4 mg) was took orally.
Study NCT06659484 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment
Description: Evaluation carried out during a day hospital at T0 (initial assessment) and T3 (after the exercise program at around 3 months) including:~1. Clinical assessment by a geriatrician~   * Medical history; systematic search for symptomatic elements (asthenia, anorexia, weight loss); research into antecedents (chronic pathologies, etc.), treatments, lifestyle, eating habits, sedentary lifestyle,~  * Complete clinical examination: particularly of the musculoskeletal system, morphological data (weight and height, calf circumference), analysis of risk of falls,~  * Current medical treatments~  * Autonomy for basic activities (ADL), instrumental activities of daily living (IADL), visual disorders, hearing impairment, etc.~  * Assessment of comorbidities (Charlson score)~  * Screening for sarcopenia (using the SARC-F questionnaire),~  * An inventory of falls and their traumatic consequences,~  * Assessment of frailty status using FRIED criteria,~2. Nutritional assessment :~   * nutritional status will also be asses
Study NCT00096070 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy
Study NCT00096070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT00096070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT00096070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT06659484 — intervention group
Intervention type: OTHER
Intervention: Multicomponent exercise program
Description: After inclusion in the protocol, participants with mobility disability risk factors are assigned to specialized and experienced kinesiologists at the end of the medical consultation.~Patients will be invited to take part in group-based exercise sessions, in small groups of no more than 10 patients, under the supervision of a kinesiologist. There will be 20 sessions over 10 weeks, at a rate of 2 sessions per week, each lasting one hour. The Multicomponent exercise program included progressive resistance and balance training.
Study NCT04068714 — intervention group
Intervention type: PROCEDURE
Intervention: Type of aneurysm repair
Description: In open surgery repair group, aneurysm repair was performed by open surgery including aortobifemoral bypass, aorto-bi-iliac bypass and tubular aortic bypass. In endovascular repair (EVAR group), aneurysm correction was performed by percutaneous approach, femoral cutdowns and aorto-uni-iliac EVARs with femorofemoral bypass.
Study NCT02559921 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rhRIG（20 IU/kg）
Study NCT02559921 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rhRIG（40 IU/kg）
Study NCT02737371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318 Dose level B oral
Description: F901318 adverse events days 1-10
Study NCT02737371 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo dose level B oral
Description: Placebo adverse events days 1-10
Study NCT02737371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318 Dose level C oral
Description: F901318 adverse events days 1-10
Study NCT02737371 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Dose level C oral
Description: Placebo adverse events days 1-10
Study NCT02384928 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Shinbaro pharmacopuncture
Description: Pharmacopuncture is a treatment that combines 2 of the most frequented Korean medicine treatment methods - traditional acupuncture and herbal medicine - by injecting herbal medicine extract at acupoints. One Hyeopcheok (Huatuo Jiaji, EX B2) acupoint most relevant to patient symptoms with reference to MRI will be administered Shinbaro pharmacopuncture.
Study NCT02384928 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Five acupoints will be needled to about 1cm depth assisted by an acupuncture guide tube with no manual stimulation such as twirling or lifting and thrusting.
Study NCT02384928 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Five acupoints will be needled to about 1cm depth assisted by an acupuncture guide tube with no manual stimulation such as twirling or lifting and thrusting.
Study NCT02384928 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional medicine
Description: Conventional drugs will be prescribed in an individually-tailored, pragmatic method with reference to most frequently used treatments in patients with a primary diagnosis of LDH (KCD disease classification: M51, M541) according to Korean Health Insurance Review and Assessment (HIRA) 2011 statistics. The most frequently prescribed conventional drugs for LDH include aceclofenac (Drug class: nonsteroidal antiinflammatoy drugs (NSAIDs)), tramadol hydrochloride (Drug class: Opioids), talniflumate (Drug class: NSAIDs), diclofenac sodium (Drug class: NSAIDs), and loxoprofen sodium (Drug class: NSAIDs).
Study NCT02384928 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: Physical therapy will be prescribed with reference to most frequently used treatments in patients with a primary diagnosis of LDH (KCD disease classification: M51, M541) according to Korean Health Insurance Review and Assessment (HIRA) 2011 statistics.
Study NCT02384928 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational program
Description: Educational program sessions supervised by physicians will be provided once a week for 4 weeks.The education program will inform the patient of the favorable prognosis of LDH, and instructions for everyday activities and self-management. The education program will consist of handbooks handed out to each participant, and weekly reminders and encouragement from the physician.
Study NCT02384928 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational program
Description: Educational program sessions supervised by physicians will be provided once a week for 4 weeks.The education program will inform the patient of the favorable prognosis of LDH, and instructions for everyday activities and self-management. The education program will consist of handbooks handed out to each participant, and weekly reminders and encouragement from the physician.
Study NCT00376675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate hydrochloride
Description: Given orally
Study NCT00376675 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT02744781 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumbar disc degeneration; LDD
Description: All MR images, taken at 5 lumbar intervertebral disc levels from the first lumbar (L1) vertebra to the first sacral vertebra (S1), were independently evaluated by 2 experienced orthopedic specialists in a random order using a grading system for LDD assessment. Using a comprehensive grading system for LDD, discs were classified into 5 grades, as described by Pfirrman et al. This system uses characteristics of disc structure, distinction between the nucleus and annulus, MRI signal intensity, and intervertebral disc height for grading, and has been accepted as a standardized and reliable evaluation tool for assessment of MRI disc morphology.
Study NCT00596895 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Isoflavone
Description: Ingested 47 mg of isoflavone in three 8 oz servings per day
Study NCT03209791 — intervention group
Intervention type: OTHER
Intervention: Biopsies
Description: Biopsy will be done on the Vastus Lateralis muscle in all groups
Study NCT00951119 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resperate
Description: device-guided breathing exercises
Study NCT00951119 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Resperate
Description: breathing device without slowing of breathing frequency
Study NCT00954824 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endotoxin (LPS)
Description: Single administration low-dose (3 ng/kg) endotoxin (LPS).
Study NCT03865849 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cooled radiofrequent treatment
Description: In the cooled radiofrequency group a treatment of 60°C measured at the tip and on average 80°C in the targeted tissue is applied during 150 seconds using the Coolief system.
Study NCT06659484 — intervention group
Intervention type: OTHER
Intervention: Follow-up at T3 + 6 months and T3 + 12 months
Description: Follow-up at T3 + 6 months :~- After the T3 visit, patients will either be redirected to independent practice (booklet) or to relay structures. At T3 + 6 months (6 months after the 3-month visit), the kinesiologists will call each patient to assess their compliance with the program, any difficulties encountered, any falls (and their severity and consequences), fear of falling, their level of ADL/IADL autonomy, level of PA practice (RAPA), presence of frailty appreciation (FRIED), whether or not they have entered an institution.~Follow-up at T3 + 12 months :~At T3+12 months (12 months after the 3-month visit), patients will be seen again by the kinesiologists to make a final assessment of their physical and functional conditions, with measurements (Handgrip, SPPB, TUG, gait parameters, leg strength) and questionnaires (SarQol and FES-I).~Patients will only be seen again by the kinesilogists, as this is mainly a check-up and final advice visit, to continue the exercises performed since.
Study NCT03865849 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional radiofrequent treatment
Description: In the conventional radiofrequency group a treatment of 80°C at the tip is applied during 90 seconds at each nerve.
Study NCT02052908 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02052908 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02052908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Given PO
Study NCT02052908 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Administration
Description: Given PO
Study NCT02052908 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study NCT06188728 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: effect of 10 gm psyllium husk fiber twice a day, 30 minutes before breakfast and dinner
Description: comparing the effect of psyllium husk fiber and lifestyle modification alone with the combined effect of psyllium husk fiber on metabolic health of centrally obese school teachers
Study NCT06188728 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Effect of life style modification (Diet, Behavior and physical activity)
Description: To assess the effect of life style modification (Diet, Behavior and physical activity) on centrally obese school teachers
Study NCT06188728 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combined effect of 10 gm Psyllium husk fiber and lifestyle modification
Description: To evaluate the combined effect of 10 gm psyllium husk fiber in gel form, 30 minutes before breakfast and dinner along with dietary, behavioral and physical activity modification on centrally obese school teachers
Study NCT06188728 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: No intervention
Study NCT04451694 — intervention group
Intervention type: OTHER
Intervention: nutritional intervention
Description: nutritional evaluation and intervention and orientation towards adapted care establishment
Study NCT00922038 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cash reward
Description: Enrollees testing negative for treatable sexually transmitted infections will receive cash rewards.
Study NCT02559921 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HRIG（20 IU/kg）
Study NCT02559921 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rhRIG（20 IU/kg） and vaccine
Study NCT02559921 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rhRIG（40 IU/kg） and vaccine
Study NCT02559921 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HRIG（20 IU/kg） and vaccine
Study NCT02559921 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo and vaccine
Study NCT01908374 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHA-rich fish oil versus Phospholipid-rich fish oil
Description: This randomized, controlled crossover study will include four treatment visits (visits 2, 3, 4, and 5; days 0, 14, 42, and 56). Subjects will be randomly assigned, by sex and age, to their first treatment study product (active or control), which will be administered with a standardized low-choline, DHA-, EPA- free breakfast meal at t = 0 h. Subjects will consume placebo or phospholipid-rich fish oil for two weeks, washed out for 4 weeks, then treatments switched. Blood samples will be obtained for acute measurements on visits 2 and 4, via an indwelling venous catheter or venipuncture at t = 1, 2, 4, 6, 8, 10, and 12 h ± 5 min, to determine plasma fatty acid profile. Chronic fatty acid measurements will be determined after 2 weeks on visits 3 and 5.
Study NCT01908374 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA-rich fish oil versus Phospholipid-rich fish oil
Description: This randomized, controlled crossover study will include four treatment visits (visits 2, 3, 4, and 5; days 0, 14, 42, and 56). Subjects will be randomly assigned, by sex and age, to their first treatment study product (active or control), which will be administered with a standardized low-choline, DHA-, EPA- free breakfast meal at t = 0 h. Subjects will consume placebo or phospholipid-rich fish oil for two weeks, washed out for 4 weeks, then treatments switched. Blood samples will be obtained for acute measurements on visits 2 and 4, via an indwelling venous catheter or venipuncture at t = 1, 2, 4, 6, 8, 10, and 12 h ± 5 min, to determine plasma fatty acid profile. Chronic fatty acid measurements will be determined after 2 weeks on visits 3 and 5.
Study NCT04059978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CBD
Description: 1600mg cannabidiol, single oral dose (8 ml oily solution)
Study NCT04059978 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo p.o, single oral dose (8 ml oily solution)
Study NCT03175250 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Videos (AIDSvideos.org) were presented on individually-assigned laptops and covered HIV risk, condom use, safe sex, and infection testing
Study NCT03175250 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Action Plan
Description: Participants selected situations for condom use and screening for HIV and hepatitis on individually-assigned laptops. They linked these situations to preventive behaviors regarding screening and condom use.
Study NCT03175250 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory Practice
Description: Participants engaged in several different types of memory practice procedures on assigned laptops. The procedures focused on memory for action plans for screening and condom use.
Study NCT00493844 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise testing
Description: Exercise testing
Study NCT00493844 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical evaluation + NTproBNP
Description: Clinical evaluation + NTproBNP levels
Study NCT01729676 — intervention group
Intervention type: DRUG
Intervention: Degarelix or GnRH agonist
Description: Degarelix or GnRH agonist for treatment of prostate cancer according to physicians current practice
Study NCT01976585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhuFlt3L/CDX-301
Description: rhuFlt3L/CDX-301 is a truncated, soluble, recombinant human fms-like tyrosine kinase-3 ligand (Flt3L), expressed in a Chinese hamster ovary cell.~RhuFlt3L/CDX-301 is formulated as a sterile solution intended for single-use parenteral administration. Each vial contains 2.5 mg/mL rhuFlt3L/CDX-301 in a 1 mL of buffered solution composed of Sodium Phosphate and Sodium Chloride, with a pH of 7.
Study NCT01976585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly-ICLC
Description: Poly-ICLC is supplied by Oncovir in single-dose vials containing 1 mL of 2 mg/mL opalescent white suspension. Each milliliter of Poly-ICLC for injection contains 2 mg/mL poly-IC, 1.5 mg/mL poly-L-lysine, and 5 mg/mL sodium carboxymethylcellulose in 0.9% sodium chloride solution and adjusted to pH 7.6-7.8 with sodium hydroxide.
Study NCT03540641 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MagVenture MagPro R30
Description: the subjects will receive 1500 or 5000 pulses at 5Hz
Study NCT03540641 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: MagVenture MagPro R30
Description: the subjects will receive 1500 or 5000 pulses at 5Hz
Study NCT01144741 — intervention group
Intervention type: OTHER
Intervention: PTSD Checklist-Civilian (PCL-C)
Description: Completed by patients before the interview; it is a 17-item survey listing of symptoms of posttraumatic stress disorder.
Study NCT01144741 — intervention group
Intervention type: OTHER
Intervention: Modified Flanagan Quality of Life Scale
Description: Completed by patients before the interview; it is a 16-item survey designed for use in persons with chronic illness.
Study NCT01144741 — intervention group
Intervention type: OTHER
Intervention: Center for Epidemiologic Studies Depression Scale (CES-D)
Description: Completed by patients before the interview; it is a 20-item survey that asks about depressive feelings and behaviours in the past week.
Study NCT01144741 — intervention group
Intervention type: OTHER
Intervention: Functional Enquiry (or Review of Systems) Form
Description: Completed during the interview; it is a checklist of medical problems.
Study NCT04580836 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04580836 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04580836 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT01144741 — intervention group
Intervention type: OTHER
Intervention: Study of Therapeutic Outcomes and Practices in Freeman-Sheldon Syndrome (STOP-FSS) Questionnaire
Description: The STOP Questionnaire is a guided interview form that will be used to assess diagnosis, problems, treatments, and outcomes.
Study NCT04059978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil 0.1 µg/kg/min i.v. for 30 min
Study NCT04059978 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil 0.1 µg/kg/min i.v. for 30 min
Study NCT01919723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor loading dose
Study NCT01919723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eptifibatide
Description: i.v. infusion